UNSPSC 51293008: Protriptyline

This classification denotes a tricyclic antidepressant with the molecular formula C19H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4NDU154T12, chemically known as 7-(3-methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene but generally known as protriptyline, which bears US NIH Compound Identifier 4976. European Medicines Agency schedules Protriptyline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10145MIG. The term PROTRIPTYLINE is an International Non-Proprietary Name.

UNSPSC 51293008 Protriptyline is a Commodity code that nominally covers a specific tricyclic antidepressant pharmaceutical, but recent state and local procurement activity tagged under this code does not reflect purchases of protriptyline itself. Instead, the recent opportunities show solicitation for naloxone (an opioid antagonist used in overdose response), generic multi-source pharmaceuticals and OTC products through cooperative purchasing frameworks, and exploratory vendor capabilities for direct-to-manufacturer prescription programs. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). Procurement activity spans health-focused commodity sourcing, typically through competitive IFB and RFP processes with multi-year contract terms and renewal options, insurance and compliance requirements, and delivery or distribution logistics.

Geographic activity concentrates in Florida, Texas, and Minnesota with participation from Oregon through the cooperative purchasing vehicle. Representative recent opportunities include Seminole County's July 2026 IFB (IFB60459723LAS) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2023; the Texas Health and Human Services Commission's April 2026 RFI (HHS0017013) seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and wholesaler channels; and MMCAP's January 2026 RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring NDC codes, compliance with cGMP and DSCSA standards, and pricing through authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC. The code shows little relevant recent activity for protriptyline specifically and appears to capture broader state and local pharmaceutical procurement under a misaligned commodity classification.